Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative Zoledronate in Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of non-metastatic operable primary invasive TN breast cancer subjected to diagnostic core biopsy~* TNBC defined as HER2/ER/PgR negative receptors~* Ki67 and p53 expression determined by IHC~* Tumour tissue availability at time of diagnosis for IHC evaluation of p53/PIN1, YAP/TAZ and Ki67 protein expression and for RT-PCR molecular testing of critical genes: p53/PIN1, YAP/TAZ~* Age ≥ 18 years old~* ECOG (Eastern Cooperative Oncology Group) performance status ≤ 1~* Patients with reproductive potential. Female patients must have a negative serum pregnancy test within 7 days prior to start of trial. Patients must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months (female patients) and 6 months (male patients) after discontinuation of treatment~* Written informed consent signed prior to enrolment according to ICH/GCP.~Exclusion Criteria:~* Presence of metastatic disease~* Clinical indication of debulking neo-adjuvant treatment~* Previous investigational treatment for any condition within 4 weeks from study registration~* Treatment with bisphosphonates, denosumab or other drug that, in the Investigator's judgment, affects bone metabolism~* Treatment with statins or other drugs that, in the Investigator's judgment, potentially affect the mevalonate pathway~* Any previous treatment for the currently diagnosed breast cancer, including radiation therapy, chemotherapy, biotherapy and/or hormonal therapy~* Inadequate bone marrow, hepatic or renal function including the following~  1. Hb\< 9.0 g/dL, absolute neutrophil count \< 1.5 x 109/L, platelets \<100 x 109/L~ 2. Total bilirubin \> 1.5 x ULN, excluding cases where elevated bilirubin can be attributed to Gilberts Syndrome~ 3. AST (SGOT), ALT (SGPT) \> 2.5 x ULN Creatinine \> 1.2 x ULN, calcium \<8.6mg/dL~* Co-existing active infection or serious concurrent illness that, at the judgment of the investigator, contra-indicate the inclusion of the patient in the study~* Co-existing dental diseases that form a contraindication to the use of zol or need for immediate dental work~* Any medical or other condition that in the investigator's opinion renders the patient unsuitable for this study due to unacceptable risk~* Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study assessment and procedures~* Anticipation of need for major surgical procedure during the course of the trial~* Known hypersensitivity to any excipients of zoledronate~* Pregnant or breast feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronate (Type: EXPERIMENTAL): Patients fulfilling the eligibility criteria will receive a pre-operative, single administration of zoledronate (4mg i.v.), 7 days before definitive breast surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues